Search Results - "Flatt, P.R."

Glucagon-like peptide 1 (GLP-1) by Müller, T.D., Finan, B., Bloom, S.R., D'Alessio, D., Drucker, D.J., Flatt, P.R., Fritsche, A., Gribble, F., Grill, H.J., Habener, J.F., Holst, J.J., Langhans, W., Meier, J.J., Nauck, M.A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D.A., Schwartz, T.W., Seeley, R.J., Stemmer, K., Tang-Christensen, M., Woods, S.C., DiMarchi, R.D., Tschöp, M.H.

“…The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the…”
Get full text

Direct and indirect effects of obestatin peptides on food intake and the regulation of glucose homeostasis and insulin secretion in mice by Green, B.D., Irwin, N., Flatt, P.R.

“…Obestatin is a recently discovered peptide hormone that appears to be involved in reducing food intake, gut motility and body weight. Obestatin is a product of…”
Get full text

The effects of traditional antidiabetic plants on in vitro glucose diffusion by Gallagher, A.M, Flatt, P.R, Duffy, G, Abdel-Wahab, Y.H.A

“…Plants represent a vast source of potentially useful dietary supplements for improving blood glucose control and preventing long-term complications in type 2…”
Get full text

239 Establishment of an F508del pseudoislet model for the study of CF-related diabetes by McClenaghan, N.H, Flatt, P.R, Harper, A.G.S, Kelly, C

Get full text

Pituitary adenylate cyclase-activating peptide (PACAP): Assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential by Green, B.D., Irwin, N., Flatt, P.R.

“…Pituitary adenylate cyclase-activating peptide (PACAP) is a member of the glucagon family of peptides. Like other members, most notably glucagon-like peptide-1…”
Get full text

PYY (3-36) protects against high fat feeding induced changes of pancreatic islet and intestinal hormone content and morphometry by Sridhar, A., Khan, D., Flatt, P.R., Irwin, N., Moffett, R.C.

“…Prolonged high fat feeding negatively impacts pancreatic and intestinal morphology. In this regard, direct effects of PYY(3–36) on intestinal cell and…”
Get full text

Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice by Owolabi, A.I., Corbett, R.C., Flatt, P.R., McKillop, A.M.

“…G-protein coupled receptor-120 (GPR120; FFAR4) is a free fatty acid receptor, widely researched for its glucoregulatory and insulin release activities. This…”
Get full text

C-terminal degradation of PYY peptides in plasma abolishes effects on satiety and beta-cell function by Lafferty, R.A., Flatt, P.R., Irwin, N.

“…[Display omitted] The importance of dipeptidyl peptidase-4 mediated N-terminal metabolism of the enteroendocrine-derived hormone, peptide YY (PYY), for…”
Get full text

MicroRNA regulation of islet and enteroendocrine peptides: Physiology and therapeutic implications for type 2 diabetes by Carr, E.R., Higgins, P.B., McClenaghan, N.H., Flatt, P.R., McCloskey, A.G.

“…The pathogenesis of type 2 diabetes (T2D) is associated with dysregulation of glucoregulatory hormones, including both islet and enteroendocrine peptides…”
Get full text

Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential by Pathak, N.M., Pathak, V., Gault, V.A., McClean, S., Irwin, N., Flatt, P.R.

“…[Display omitted] Glucose-dependent insulinotropic hormone (GIP) and glucagon-like peptide-1 (GLP-1) are incretin hormones that exert an array of beneficial…”
Get full text

Pharmacological potential of novel agonists for FFAR4 on islet and enteroendocrine cell function and glucose homeostasis by McCloskey, A.G., Miskelly, M.G., Flatt, P.R., McKillop, A.M.

“…To investigate the metabolic effects of FFAR4-selective agonists on islet and enteroendocrine cell hormone release and the combined therapeutic effectiveness…”
Get full text

Antagonism of gastric inhibitory polypeptide (GIP) by palmitoylation of GIP analogues with N- and C-terminal modifications improves obesity and metabolic control in high fat fed mice by Pathak, V., Gault, V.A., Flatt, P.R., Irwin, N.

“…•GIP(3-30)Cex-K40[Pal] and Pro3GIP(3-30)Cex-K40[Pal] are stable GIP inhibitors.•Both peptides reduce body weight, circulating glucose and insulin in high fat…”
Get full text

Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance by Porter, D.W, Kerr, B.D, Flatt, P.R, Holscher, C, Gault, V.A

“…Aim: Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) mimetic which is a treatment option for type 2 diabetes. GLP-1 peptides, including…”
Get full text

Effects of nateglinide on the secretion of glycated insulin and glucose tolerance in type 2 diabetes by Lindsay, J.R., McKillop, A.M., Mooney, M.H., O'Harte, F.P.M., Flatt, P.R., Bell, P.M.

“…Aims: Glycation of insulin has been demonstrated within pancreatic β-cells and the resulting impaired bioactivity may contribute to insulin resistance in…”
Get full text

Apelin-13 analogues show potent in vitro and in vivo insulinotropic and glucose lowering actions by O’Harte, F.P.M., Parthsarathy, V., Hogg, C., Flatt, P.R.

“…•N- and C-terminally structurally modified peptide analogues of apelin-13 are more stable than the native peptide and retain bioactivity.•Apelin-13 analogues…”
Get full text

Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice by Porter, W D, Flatt, P R, Hölscher, C, Gault, V A

“…Objective: Consumption of high-fat diet exerts adverse effects on learning and memory formation, which is linked to impaired hippocampal function. Activation…”
Get full text

A GIP/xenin hybrid in combination with exendin-4 improves metabolic status in db/db diabetic mice and promotes enduring antidiabetic benefits in high fat fed mice by Craig, S.L., Perry, R.A., Vyavahare, S.S., Ng, M.T., Gault, V.A, Flatt, P.R, Irwin, N.

“…[Display omitted] The current study has determined the ability of exendin-4 to augment the antidiabetic benefits of the recently characterised GIP/xenin…”
Get full text

Antidiabetic effects and sustained metabolic benefits of sub-chronic co-administration of exendin-4/gastrin and xenin-8-Gln in high fat fed mice by Hasib, A., Khan, D., Craig, S.L., Gault, V.A., Flatt, P.R., Irwin, N.

“…The present study has examined the antidiabetic effects of 21 days co-administration of xenin-8-Gln with the dual-acting fusion peptide, exendin-4/gastrin, as…”
Get full text

CRISPR/Cas9 gene editing demonstrates metabolic importance of GPR55 in the modulation of GIP release and pancreatic beta cell function by McCloskey, A.G., Miskelly, M.G., Moore, C.B.T., Nesbit, M.A., Christie, K.A., Owolabi, A.I., Flatt, P.R., McKillop, A.M.

“…•CRISPR/Cas9 gene editing has determined the specificity of a number of endogenous and synthetic cannabinoid agonists.•The CRISPR tool has determined…”
Get full text

Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice by Pathak, N.M., Pathak, V., Lynch, A.M., Irwin, N., Gault, V.A., Flatt, P.R.

“…•(dS2)Oxm[K-γ-glu-Pal] and (dS2)Oxm enhanced hippocampal neurogenesis.•Both Oxm peptides improved hippocampal synaptophysin staining.•Hippocampus and cortex…”
Get full text